Danavorexton
| Clinical data | |
|---|---|
| Other names | TAK-925 | 
| Routes of administration | Intravenous | 
| Drug class | Orexin receptor agonist | 
| Pharmacokinetic data | |
| Elimination half-life | ~3.3–5.1 h | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H32N2O5S | 
| Molar mass | 424.56 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
Danavorexton (developmental code name TAK-925) is a selective orexin 2 receptor agonist. It is a small-molecule compound and is administered intravenously. The compound was found to dose-dependently produce wakefulness to a similar degree as modafinil in a phase 1 clinical trial. As of March 2021, danavorexton is under development for the treatment of narcolepsy, idiopathic hypersomnia, and sleep apnea. It is related to another orexin receptor agonist, firazorexton (TAK-994), the development of which was discontinued for safety reasons in October 2021.